Oncology

Bevacizumab: New Standard for Non-Small Cell Lung Cancer?

Christian Manegold
Christian Manegold
Nick Thatcher
Nick Thatcher
Christian Manegold, Heidelberg University Medical Center, Manheim
Nick Thatcher, Christie Hospital, Manchester

Is bevacizumab a new standard of care for patients with unresectable non-small cell lung cancer who have good performance status? This question was raised in a debate at the European Congress on Lung Cancer held in Turin. Christian Manegold provided delegates with evidence from the AVAil and ECOG 4599 studies which underpin current approval of this anti-vascular endothelial growth factor (VEG-F) antibody. Nick Thatcher pointed out the limitations. They both talked with Peter Goodwin.

Download this interview

Similar Interviews

  • Front Line Therapy in Non-Small Cell Lung Cancer
  • Nick Thatcher NICK THATCHER, Christie Hospital, Manchester There is a proven benefit in survival

  • Audio Journal of Oncology 12.7, September 2004
  • Reporting from: - 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, June 5-8, 2004 - New England Journal

  • Debate: Adjuvant Chemotherapy Should Be Standard in Stage I Non-Small Cell Lung Cancer
  • Giorgio Scagliotti Robert Pirker GIORGIO SCAGLIOTTI, University of Turin

    Post a comment